Bafna Pharmaceuticals today said it has received approval from Sri Lankan authorities to launch its anti-hypertension product, Olmebaf, in the island nation.
The company will market the brand by early 2010, the Chennai-based drug maker said in a statement to the Bombay Stock Exchange (BSE).
Bafna Pharma also said it will sell its product directly through its own front end. This will increasingly supplement the company's revenue stream which has traditionally relied on the generics market.
"We will continue to expand our product range in the coming months by developing products where we are vertically integrated," Bafna Pharma Chairman and Managing Director Mahaveer Chand Bafna said.
Shares of Bafna Pharma today settled at Rs 31, up 2.31 per cent in on the BSE.